Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BRCX014
- Development stage
- Unknown
- Lead developer
- Diverse Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BRCX014 is a specific formulation of cannabidiol (CBD) being developed by Leaf Vertical Inc. for the treatment of glioblastoma multiforme (GBM) and other cancers. As a small molecule therapeutic, it is being investigated as an adjunct to standard-of-care treatments, including temozolomide-based chemotherapy, radiation therapy, and alternating electric-field therapy (Optune). The drug is particularly focused on glioblastoma patients with non-methylated MGMT promoter status, a population typically resistant to standard alkylating agents. BRCX014 is hypothesized to exert anti-tumor effects by modulating various cell signaling pathways, inhibiting angiogenesis, inducing apoptosis, and potentially sensitizing glioma cells to conventional chemotherapy.
- Other names
- cannabidiol
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))ABCG2 (Breast cancer resistance protein)CNR1 (Cannabinoid receptor 1)GPR55 (G protein-coupled receptor 55)PPARG (Peroxisome proliferator-activated receptor gamma)TRPV1 (Transient receptor potential cation channel subfamily V member 1)DOR (Opioid Receptor Delta 1)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on BRCX014.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BRCX014.